Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638495 | 1.00 | PRCP (0.39) | PRCPBMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL16644633 | 1.00 | PRCP (0.39) | PRCPBMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL14258976 | 0.80 | BMPR1B (0.34) | BMPR1BPDGFRBKDRACVR1BTGFBR1 | |
| SCHEMBL1639188 | 0.80 | MAPT (0.43) | PRCPBMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL29104079 | 0.80 | MAPT (0.43) | KDM1ATDP1HTR2AHTR2C | |
| SCHEMBL10563871 | 0.80 | PARP1 (0.35) | BMPR1BPDGFRBKDRACVR1BTGFBR1 | |
| SCHEMBL263978 | 0.80 | HTR3A (0.53) | PRCP | |
| SCHEMBL552751 | 0.80 | MAPT (0.43) | KDM1ATDP1HTR2AHTR2C | |
| SCHEMBL1673686 | 0.80 | HTR3A (0.53) | PRCP | |
| SCHEMBL9786119 | 0.80 | MAPT (0.43) | PRCPBMPR1BPDGFRBKDRACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177617-B1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016022521-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| EP-1851199-B1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-7625889-B2 | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080138413-A1 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1928442-A2 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| WO-2007024600-A2 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| US-5053509-A | Microbiocides; AIDS | LABORATOIRE ROGER BELLON (FR) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138413-A1 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | HCRTR1, HCRTR2, MTNR1B | PRCP 2938/4885BMPR1B 973/4885PDGFRB 2379/4885 |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | PRCP 800/4885BMPR1B 2778/4885PDGFRB 1382/4885 |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | HTR2A, HTR2B, HTR2C | PRCP 2851/4885BMPR1B 553/4885PDGFRB 488/4885 |
| US-20170226067-A1 | PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | NR1H2, NR1H3, NR1I2 | PRCP 1647/4885BMPR1B 950/4885PDGFRB 552/4885 |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | PRCP 3761/4885BMPR1B 940/4885PDGFRB 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.